Compare AIXI & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIXI | CDT |
|---|---|---|
| Founded | 2001 | 2019 |
| Country | China | United States |
| Employees | N/A | 4 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.8K | 181.2K |
| IPO Year | 2022 | 2022 |
| Metric | AIXI | CDT |
|---|---|---|
| Price | $2.86 | $0.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 4.5M | 1.7M |
| Earning Date | 05-15-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.07 |
| 52 Week High | $16.28 | $88,750.00 |
| Indicator | AIXI | CDT |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 21.39 |
| Support Level | $0.47 | $0.07 |
| Resistance Level | $3.38 | $170.00 |
| Average True Range (ATR) | 0.56 | 0.12 |
| MACD | 0.13 | 4.30 |
| Stochastic Oscillator | 68.22 | 2.35 |
XIAO-I Corp operates as a cognitive artificial intelligence company. Using its proprietary intellectual property technologies, the company has developed and commercialized various core technologies, such as Conversational AI, Knowledge Fusion, Intelligence Voice, Hyperautomation, Data Intelligence, Cloud, Intelligent Construction Support, Vision Analysis, Intelligent Hardware Support, and Metaverse. Additionally, it has developed Hua Zang Universal Large Language Model. XIAO-I offers two different product lines: Model as a service (MaaS) and non-MaaS. Key revenue is derived from the non-MaaS product line, which comprises needs assessment, solution design and architecture planning, development and configuration, deployment, and implementation of non-model (mainly cloud platform) products.
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.